KRAS and pancreatic adenocarcinoma: Likewise, the PAAD patients with KRAS G12D plus TP53 co-mutations had much shorter OS (median OS, 369 vs. 633 days; HR, 1.81; 95% CI, 1.28–2.56; P=0.0001) than that of other PAAD patients in ICGC cohort (N=235) (Supplementary Fig. S9C, Supplemental Digital Content 3, http://links.lww.com/JS9/A234).